Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Trouble For Expanded Use of Cymbalta

Posted by Jane Akre
Tuesday, January 05, 2010 3:10 PM EST
Category: Major Medical
Tags: Eli Lilly, Cymbalta, Zyprexa, FDA, DOJ, Antidepressant

Cymbalta will not receive a January review by an expert panel for expanded use.

Expert Panel Cancels Meeting

LEARN MORE


IMAGE SOURCE: Wikimedia Commons/ Cymbalta/ author: Military ace

Eli Lilly & Co’s popular antidepressant, Cymbalta, will not get an expert panel review by the Food and Drug Administration to consider the drug as a treatment for pain.

The agency canceled the January 28 meeting of the FDA’s anesthetic and life support drugs advisory committee, reports the Wall Street Journal, “to allow time for the FDA to review new information that is relevant to the benefit risk balance for the proposed new indication.”

Lilly may be granted a future advisory panel meeting in response to its June 2009 application that contained additional information from clinical trials on using the drug to treat lower back pain and osteoarthritis pain. The FDA does not have to follow the recommendation of its expert panels but often does.

This is not the first setback for Lilly concerning Cymbalta. In November 2008, Lilly withdrew an FDA application after the agency questioned how the drug was tested to treat the chronic pain caused by osteoarthritis and lower back pain.

Cymbalta is only approved currently to treat depression, anxiety disorder, diabetic nerve pain and fibromyalgia. It is the second-best seller for Lilly behind Zyprexa, an antipsychotic. Cymbalta earned more than $2.7 billion in sales in 2008, but its patent expires in three years. The patent for Zyprexa expires next year, so the company is looking for new applications can extend the popularity of a drug.

Doctors can still prescribe it off label for other conditions other than that for which it is approved.

Lilly shares were down in afternoon trading.

Lilly’s Record $1.415 Billion Fine

Last January, Lilly had to pay a record $1.415 billion civil penalty for off-label drug marketing, the largest amount paid by a single defendant at that time in the history of the U.S. Department of Justice (DOJ).

Lilly admitted that its sales force targeted doctors at nursing homes and illegally marketed Zyprexa for uses never approved by the FDA, including treating the elderly for sleep disorders, Alzheimer’s disease, aggression, hostility, depression, and dementia.

Zyprexa was never approved for any of those disorders, but is approved for bipolar disorder and schizophrenia.

Lilly reps emphasized that the weight gain side effect would be of benefit to some patients who had trouble maintaining their weight.

IB member attorney Stephen Sheller filed the first complaint in February 2003. The allegations originated from six former Lilly drug marketing representatives who became whistleblowers.

Lilly perpetrated fraud on the public, says Sheller, while the whistleblowers complained within the company about Lilly’s improper marketing practices. All six were eventually fired or forced to resign. #


1 Comment

Posted by Daniel Haszard
Wednesday, January 06, 2010 4:01 AM EST

Eli Lilly sells a drug (Zyprexa) that can cause diabetes and then turn a profit on the drugs that treat the condition that they may have caused in the first place!

Eli Lilly has made $38 billion on Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.
Eli Lilly has received a huge criminal fine over their Zyprexa cash cow,add it all up comes to $4.6 billion, in Zyprexa settlements,fines,litigation.

Addictive Zyprexa was pushed by Lilly Drug Reps.
They called it the “Five at Five” (5 mg at 5 pm to keep nursing home patients subdued and sleepy) and “VIVA ZYPREXA” (Zyprexa for everybody) campaigns to off label market Eli Lilly Zyprexa as a fix for unapproved usage.

—-
Daniel Haszard Zyprexa whistle-blower

WARNING-
If a drug (Zyprexa) lists anything about the pancreas among the side effects, it probably means it can cause diabetes.
Unlike your liver, the pancreas does not regenerate itself. If it gets damaged, diabetes is very likely

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes